Cassava Sciences (NASDAQ:SAVA) stock illustrates the promise — and hazards — in biotechnology investing. Casssava management says it has a drug that can effectively treat Alzheimer’s Disease, one of the most destructive diseases known to man. They may have it, or they may not. It’s impossible for a small investor like me to know for sure when it comes to SAVA stock.
Specifically, Cassava launched another Phase 3 trial on its Alzheimer’s compound, Simufilam, back in November. The company also has a website to support the study. According to SAVA, the drug can fix abnormalities in a protein called filamin A, or FLNA. However, according to a recent story in The New Yorker, a better name for the treatment might be Simulated Flim Flam. Some have doubts about this drug, to say the least.
Here’s what you need to know about SAVA stock moving forward.
The post Does Cassava Sciences and Its Alzheimer’s Drug Really Have What It Takes? appeared first on InvestorPlace.